Emily Bodnar’s rating is based within the anticipation of substantial milestones for Agenus in the coming year, significantly the probable filing of a Biologics License Software (BLA) for his or her lead drug candidate, botensilimab (bot). Agenus has dosed in excess of 900 clients with bot across numerous solid tumors, demonstrating a determinati